A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4779-4787

  Hong, Qi ^a,b   Yu, Sanjian ^a   Yang, Yu ^a,c   Liu, Guangyu ^a   Shao, Zhiming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Breast cancer; Caspase 3; Cleavage; JMJD2C; Polymorphism

Indexed keywords

CASPASE 3; GAMMA HISTONE H2AX; GENOMIC DNA; HISTONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENZYME ACTIVATOR; H2AFX PROTEIN, HUMAN; HISTONE DEMETHYLASE; KDM4C PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE JMJD2C; PROTEIN EXPRESSION; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY RESISTANCE; UPREGULATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BREAST TUMOR; DNA REPAIR; GENE FREQUENCY; GENETICS; GENOTYPE; HEK293 CELL LINE; HELA CELL LINE; HYDROLYSIS; KAPLAN MEIER METHOD; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DNA REPAIR; ENZYME ACTIVATORS; GENE FREQUENCY; GENOTYPE; HEK293 CELLS; HELA CELLS; HISTONES; HUMANS; HYDROLYSIS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RNA INTERFERENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905044708     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2029     Document Type: Article

References (26)

1. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH and Helin K. The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature. 2006; 442(7100):307-311.
2. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, Sugano S, Nakamura Y and Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer research. 2000; 60(17):4735-4739.
3. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP and Yang ZQ. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 2009; 28(50):4491-4500.
4. Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP and Yang ZQ. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene. 2012; 31(3):333-341.
5. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC and Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer research. 2006; 66(10):5354-5362.
6. Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M and Rosell R. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget. 2013; 4(10):1572-1581.
7. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002; 23(5):687-696.
8. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. Journal of the National Cancer Institute. 2001; 93(19):1434-1436.
9. Kennedy RD, Quinn JE, Mullan PB, Johnston PG and Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. Journal of the National Cancer Institute. 2004; 96(22):1659-1668.
10. Sun Y, Jiang X and Price BD. Tip60: connecting chromatin to DNA damage signaling. Cell cycle. 2010; 9(5):930-936.
11. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR and Price BD. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol. 2009; 11(11):1376-1382.
12. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD and Mehta K. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002; 21(57):8843-8851.
13. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA and et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995; 376(6535):37-43.
14. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995; 81(5):801-809.
15. Ribeil JA, Zermati Y, Vandekerckhove J, Cathelin S, Kersual J, Dussiot M, Coulon S, Moura IC, Zeuner A, Kirkegaard-Sorensen T, Varet B, Solary E, Garrido C and Hermine O. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature. 2007; 445(7123):102-105.
16. O'Donovan N, Crown J, Stunell H, Hill AD, McDermott E, O'Higgins N and Duffy MJ. Caspase 3 in breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(2):738-742.
17. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature medicine. 2011; 17(7):860-866.
18. Vegran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F and Lizard-Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(19):5794-5800.
19. Wesierska-Gadek J, Hackl S, Zulehner N, Maurer M and Komina O. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors. Journal of cellular biochemistry. 2011; 112(1):273-288.
20. Shin S and Janknecht R. Diversity within the JMJD2 histone demethylase family. Biochemical and biophysical research communications. 2007; 353(4):973-977.
21. Kinner A, Wu W, Staudt C and Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic acids research. 2008; 36(17):5678-5694.
22. Helias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R and Lessard M. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer genetics and cytogenetics. 2008; 180(1):51-55.
23. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer cell. 2010; 18(6):590-605.
24. Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, Flavell RA, Thomson JA and Zwaka TP. Caspase activity mediates the differentiation of embryonic stem cells. Cell stem cell. 2008; 2(6):595-601.
25. Loh YH, Zhang W, Chen X, George J and Ng HH. Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes & development. 2007; 21(20):2545-2557.
26. Kim TD, Oh S, Shin S and Janknecht R. Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PloS one. 2012; 7(4):e34618.